Hoey Investments Inc. Takes $452,000 Position in GSK plc (NYSE:GSK)

Hoey Investments Inc. bought a new position in shares of GSK plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,379 shares of the pharmaceutical company’s stock, valued at approximately $452,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dorsey & Whitney Trust CO LLC grew its position in shares of GSK by 2.5% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company’s stock valued at $389,000 after buying an additional 278 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the last quarter. Rehmann Capital Advisory Group increased its position in shares of GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares in the last quarter. GC Wealth Management RIA LLC lifted its holdings in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company’s stock valued at $474,000 after purchasing an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC boosted its position in shares of GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company’s stock valued at $352,000 after purchasing an additional 389 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Trading Up 0.6 %

NYSE:GSK opened at $38.74 on Monday. GSK plc has a 12-month low of $31.72 and a 12-month high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock’s 50 day simple moving average is $37.22 and its 200-day simple moving average is $36.69. The firm has a market cap of $80.19 billion, a P/E ratio of 24.37, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.06%. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

Analyst Ratings Changes

Several research analysts have commented on the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.